Literature DB >> 6224680

Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria.

S J Wood, S Shadomy.   

Abstract

One hundred and eighty three clinical isolates of aerobic bacteria were tested against norfloxacin by both agar dilution (WHO-ICS) and disk diffusion test procedures (standardized FDA single disk test). Two experimental 10 microgram norfloxacin disks were studied. Results were analyzed in terms of recently recommended breakpoints for clinical susceptibility (MIC less than or equal to 16 micrograms/ml, zone diameter greater than or equal to 17 mm) and resistance (MIC greater than or equal to 32 micrograms/ml, zone diameter less than or equal to 12 mm). Excellent correlation was demonstrated by statistical analysis between paired MIC and zone size values (average value for each MIC; r = -0.9782). An MIC of 16 micrograms/ml was found to correlate with a zone of 10.4 mm. Application of the recommended zone size breakpoints resulted in prediction of 177 isolates as being susceptible while six (3.3%) were predicted to be either intermediate or resistant. The findings of this study validate the earlier recommendations stated above.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224680     DOI: 10.1007/bf02029525

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  5 in total

1.  Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors:  H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

2.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

4.  Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.

Authors:  V K Boppana; B N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

5.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  5 in total
  3 in total

1.  Agar disk diffusion and automated microbroth dilution produce similar antimicrobial susceptibility testing results for Salmonella serotypes Newport, Typhimurium, and 4,5,12:i-, but differ in economic cost.

Authors:  Karin Hoelzer; Kevin J Cummings; Lorin D Warnick; Ynte H Schukken; Julie D Siler; Yrjo T Gröhn; Margaret A Davis; Tom E Besser; Martin Wiedmann
Journal:  Foodborne Pathog Dis       Date:  2011-08-30       Impact factor: 3.171

2.  Criteria for interpretation of agar diffusion susceptibility tests of norfloxacin performed by the ICS method.

Authors:  H Grimm
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

3.  Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

Authors:  E J Goldstein; M L Alpert; B P Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.